Hyrimoz 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0050 
Minor change in labelling or package leaflet not 
18/12/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0048 
B.I.b.2.z - Change in test procedure for AS or 
02/10/2023 
n/a 
starting material/reagent/intermediate - Other 
variation 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
IAIN/0047/G 
This was an application for a group of variations. 
19/09/2023 
Annex II and 
PL 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
Page 2/15 
 
 
 
 
 
 
 
 
 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
PSUSA/10783
Periodic Safety Update EU Single assessment - 
31/08/2023 
n/a 
PRAC Recommendation - maintenance 
/202212 
adalimumab 
IB/0045 
B.II.e.5.a.2 - Change in pack size of the finished 
07/08/2023 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
SmPC, 
Labelling and 
PL 
IB/0044/G 
This was an application for a group of variations. 
26/07/2023 
n/a 
B.II.e.7.a - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
IB/0043 
B.II.b.3.z - Change in the manufacturing process of 
13/06/2023 
n/a 
the finished or intermediate product - Other variation 
IG/1628/G 
This was an application for a group of variations. 
02/06/2023 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.e.1.b.3 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Deletion of an immediate packaging 
Page 3/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
container without a complete deletion of a strength 
or pharmaceutical form 
IB/0041 
B.II.e.3.b - Change in test procedure for the 
28/04/2023 
n/a 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
X/0036/G 
This was an application for a group of variations. 
26/01/2023 
31/03/2023 
SmPC, Annex 
II, Labelling 
and PL 
Annex I_2.(c) Change or addition of a new 
strength/potency 
B.II.a.5 - Change in concentration of a single-dose, 
total use parenteral product, where the amount of 
AS per unit dose (i.e. the strength) remains the 
same 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
Page 4/15 
 
 
 
 
 
 
 
 
 
 
 
storage site of MCB and/or WCB 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.b.2.d - Change in test procedure for AS or 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Page 5/15 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IG/1601 
B.II.b.5.a - Change to in-process tests or limits 
22/03/2023 
n/a 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
R/0037 
Renewal of the marketing authorisation. 
15/12/2022 
15/02/2023 
SmPC and PL 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
Hyrimoz in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IB/0038 
B.I.a.2.z - Changes in the manufacturing process of 
18/10/2022 
n/a 
the AS - Other variation 
IG/1480 
A.5.b - Administrative change - Change in the name 
02/02/2022 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
Page 6/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0034 
C.I.11.z - Introduction of, or change(s) to, the 
03/11/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0033 
C.I.2.a - Change in the SPC, Labelling or PL of a 
01/10/2021 
22/10/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
WS/1908/G 
This was an application for a group of variations 
22/07/2021 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.2.d - Change in test procedure for AS or 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
Page 7/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0031 
Type IB (B.II.f.1.d) - Removal of the ‘do not shake’ 
08/06/2021 
22/10/2021 
SmPC, 
Type IB (B.II.f.1.d) - Removal of the ‘do not shake’ warning 
warning from the PI. 
Article 61(3) notifications - Update of local 
representatives list included in the patient 
information leaflet. 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
Labelling and 
from the PI. 
PL 
Article 61(3) notifications - Update of local representatives 
list included in the patient information leaflet. 
IG/1400/G 
This was an application for a group of variations. 
31/05/2021 
n/a 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
WS/2025 
This was an application for a variation following a 
09/04/2021 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
IG/1380 
C.I.z - Changes (Safety/Efficacy) of Human and 
26/03/2021 
22/10/2021 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
Page 8/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0027 
B.IV.1.z - Change of a measuring or administration 
11/11/2020 
n/a 
device - Other variation 
IG/1290 
C.I.z - Changes (Safety/Efficacy) of Human and 
05/10/2020 
09/03/2021 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
PSUSA/10783
Periodic Safety Update EU Single assessment - 
03/09/2020 
n/a 
PRAC Recommendation - maintenance 
/201912 
adalimumab 
IG/1288 
B.I.b.1.b - Change in the specification parameters 
27/08/2020 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
IB/0023 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
20/07/2020 
09/03/2021 
SmPC and PL 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
IB/0021/G 
This was an application for a group of variations. 
17/06/2020 
n/a 
B.I.a.3.e - Change in batch size (including batch size 
ranges) of AS or intermediate - The scale for a 
biological/immunological AS is increased/decreased 
without process change (e.g. duplication of line) 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
Page 9/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0022 
B.II.e.6.b - Change in any part of the (primary) 
08/06/2020 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
X/0013 
Annex I_2.(c) Change or addition of a new 
30/01/2020 
27/03/2020 
SmPC, Annex 
strength/potency 
II, Labelling 
and PL 
IG/1190/G 
This was an application for a group of variations. 
26/03/2020 
n/a 
B.II.b.5.a - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
B.II.b.5.c - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test 
WS/1765 
This was an application for a variation following a 
05/03/2020 
09/03/2021 
SmPC 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0017 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
10/12/2019 
n/a 
storage conditions of the finished product - Other 
variation 
Page 10/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0016/G 
This was an application for a group of variations. 
26/09/2019 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
WS/1643/G 
This was an application for a group of variations 
19/09/2019 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
N/0015 
Minor change in labelling or package leaflet not 
16/08/2019 
23/09/2019 
Labelling 
connected with the SPC (Art. 61.3 Notification) 
IA/0014 
B.II.b.1.a - Replacement or addition of a 
31/07/2019 
n/a 
Page 11/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing site for the FP - Secondary packaging 
site 
IB/0011 
C.I.z - Changes (Safety/Efficacy) of Human and 
25/07/2019 
23/09/2019 
Annex II 
Veterinary Medicinal Products - Other variation 
PSUSA/10589
Periodic Safety Update EU Single assessment - 
11/07/2019 
n/a 
PRAC Recommendation - maintenance 
/201812 
adalimumab (biosimilars) 
IA/0010 
B.II.b.3.a - Change in the manufacturing process of 
11/06/2019 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
WS/1565 
This was an application for a variation following a 
28/03/2019 
23/09/2019 
SmPC, Annex 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
II, Labelling 
and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0007/G 
This was an application for a group of variations. 
21/03/2019 
n/a 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
Page 12/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.2.z - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
variation 
IB/0006 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
19/02/2019 
23/09/2019 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
WS/1479/G 
This was an application for a group of variations 
17/01/2019 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
Page 13/15 
 
 
 
 
 
 
 
 
 
 
 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
B.II.e.1.b.2 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Sterile medicinal products and 
biological/immunological medicinal products 
IAIN/0005/G 
This was an application for a group of variations. 
20/12/2018 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0004 
B.II.b.3.z - Change in the manufacturing process of 
27/11/2018 
n/a 
the finished or intermediate product - Other variation 
IAIN/0003 
B.II.b.1.a - Replacement or addition of a 
14/11/2018 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0002/G 
This was an application for a group of variations. 
15/10/2018 
23/09/2019 
SmPC, Annex 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
II, Labelling 
and PL 
Page 14/15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 15/15 
 
 
 
 
 
 
 
